Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces

Biomaterials

Volumn 33, Issue 24, 2012, Pages 5803-5811

  Finley, Matthew J ^a,b   Rauova, Lubica ^a,b   Alferiev, Ivan S ^a,b   Weisel, John W ^b   Levy, Robert J ^a,b   Stachelek, Stanley J ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomimetic material; Blood compatibility; Platelet activation; Platelet adhesion; Surface modification

Indexed keywords

BIOLOGICAL MARKERS; BLOOD CELLS; BLOOD COMPATIBILITY; C-TERMINUS; CONTACTING SURFACES; COVALENT LINKAGE; ETHYLENE OXIDE GAS; FLOW CYTOMETRY ANALYSIS; FUNCTIONALIZED; INFLAMMATORY CELLS; MODIFIED PVC; MODIFIED SURFACES; PLATELET ACTIVATION; PLATELET ADHESION; POLYLYSINE; POLYMERIC SURFACES; QUALITATIVE ANALYSIS; SELF-RECOGNITION; SIGNAL REGULATORY PROTEINS; SIGNALING MECHANISMS; TRANS-MEMBRANE PROTEINS;

ADHESION; AMINO ACIDS; BIOCOMPATIBILITY; BIOMIMETIC MATERIALS; ORGANIC COATINGS; POLYMERS; SCANNING ELECTRON MICROSCOPY; SURFACE TREATMENT;

PLATELETS;

CD47B PROTEIN; CD47L PROTEIN; L SELECTIN; PADGEM PROTEIN; POLYVINYLCHLORIDE; RECOMBINANT PROTEIN; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA 1; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; CELL ISOLATION; CONTROLLED STUDY; COVALENT BOND; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

ANTIGENS, CD47; ANTIGENS, DIFFERENTIATION; BIOCOMPATIBLE MATERIALS; BLOOD PLATELETS; CELL ADHESION; GENE EXPRESSION; HUMANS; NEUTROPHILS; PLATELET ACTIVATION; POLYVINYL CHLORIDE; RECEPTORS, IMMUNOLOGIC; SURFACE PROPERTIES;

EID: 84861733808     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.051     Document Type: Article

References (41)

1. Bruck S.D. Medical applications of polymeric materials. Med Prog Technol 1982, 9:1-16.
2. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007, 44:82-94.
3. Maitz M.F., Sperling C., Werner C. Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Arg-chloromethylketone: a concept for hemocompatible surfaces?. J Biomed Mater Res A 2010, 94:905-912.
4. Sperling C., Salchert K., Streller U., Werner C. Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro. Biomaterials 2004, 25:5101-5113.
5. Weber N., Wendel H.P., Ziemer G. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002, 23:429-439.
6. Stachelek S.J., Finley M.J., Alferiev I.S., Wang F., Tsai R.K., Eckells E.C., et al. The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Biomaterials 2011, 32:4317-4326.
7. van Beek E.M., Cochrane F., Barclay A.N., van den Berg T.K. Signal regulatory proteins in the immune system. J Immunol 2005, 175:7781-7787.
8. Tsai R.K., Discher D.E. Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 2008, 180:989-1003.
9. Tsai R.K., Rodriguez P.L., Discher D.E. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010, 45:67-74.
10. Clark S.C. Lung injury after cardiopulmonary bypass. Perfusion 2006, 21:225-228.
11. Gawaz M.P., Mujais S.K., Schmidt B., Blumenstein M., Gurland H.J. Platelet-leukocyte aggregates during hemodialysis: effect of membrane type. Artif Organs 1999, 23:29-36.
12. Gorman J.H., Edmunds L.H. Blood anesthesia for cardiopulmonary bypass. J Card Surg 1995, 10:270-279.
13. Scott D., Nitecki D.E., Kindler H., Goodman J.W. Immunogenicity of biotinylated hapten-avidin complexes. Mol Immunol 1984, 21:1055-1060.
14. Stachelek S.J., Alferiev I., Connolly J.M., Sacks M., Hebbel R.P., Bianco R., et al. Cholesterol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. Ann Thorac Surg 2006, 81:47-55.
15. Tabuchi N., Shibamiya A., Koyama T., Fukuda T., Oeveren Wv W., Sunamori M. Activated leukocytes adsorbed on the surface of an extracorporeal circuit. Artif Organs 2003, 27:591-594.
16. Grooteman M.P., Bos J.C., van Houte A.J., van Limbeek J., Schoorl M., Nube M.J. Mechanisms of intra-dialyser granulocyte activation: a sequential dialyser elution study. Nephrol Dial Transplant 1997, 12:492-499.
17. Grooteman M.P., Nube M.J., Bos J.C., van Limbeek J., Schoorl M., van Houte A.J. Ex vivo elution of hemodialyzers. An additional criterion for the assessment of bioincompatibility. Blood Purif 1996, 14:421-430.
18. Grooteman M.P., Nube M.J., van Limbeek J., Schoorl M., van Houte A.J. Lymphocyte subsets in dialyser eluates: a new parameter of bioincompatibility?. Nephrol Dial Transplant 1996, 11:1073-1078.
19. Silvain J., Collet J.P., Nagaswami C., Beygui F., Edmondson K.E., Bellemain-Appaix A., et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011, 57:1359-1367.
20. Weisel J.W., Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992, 63:111-128.
21. Olsson M., Bruhns P., Frazier W.A., Ravetch J.V., Oldenborg P.A. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005, 105:3577-3582.
22. Kasirer-Friede A., Kahn M.L., Shattil S.J. Platelet integrins and immunoreceptors. Immunol Rev 2007, 218:247-264.
23. Edmunds L.H. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998, 66:S12-S16. discussion S25-8.
24. Groom R.C. Pediatric cardiopulmonary bypass devices: trends in device use for cardiopulmonary bypass and postcardiotomy support. ASAIO J 2005, 51:525-529.
25. Pintar T., Collard C.D. The systemic inflammatory response to cardiopulmonary bypass. Anesthesiol Clin North America 2003, 21:453-464.
26. Draaisma A.M., Hazekamp M.G. Coated versus noncoated circuits in pediatric cardiopulmonary bypass. ASAIO J 2005, 51:663-664.
27. Eisses M.J., Geiduschek J.M., Jonmarker C., Cohen G.A., Chandler W.L. Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 2007, 21:28-34.
28. Hill G.E. The inflammatory response to cardiopulmonary bypass. Int Anesthesiol Clin 1996, 34:95-108.
29. Levy J.H., Tanaka K.A. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003, 75:S715-S720.
30. Harig F., Meier C., Hakami L., Strasser R., Bretzger J., Munch F., et al. Does the additional use of heparin-coated extracorporeal circuits (ECC) optimize the effect of modified ultrafiltration (MUF) in pediatric perfusion?. Thorac Cardiovasc Surg 2006, 54:168-172.
31. Losel-Sadee H., Alefelder C. Heparin-bonded expanded polytetrafluoroethylene graft for infragenicular bypass: five-year results. J Cardiovasc Surg 2009, 50:339-343. [Torino].
32. Paparella D., Yau T.M., Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002, 21:232-244.
33. Subramanian S., Parthasarathy R., Sen S., Boder E.T., Discher D.E. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006, 107:2548-2556.
34. Yamao T., Noguchi T., Takeuchi O., Nishiyama U., Morita H., Hagiwara T., et al. Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem 2002, 277:39833-39839.
35. Isenberg J.S., Roberts D.D., Frazier W.A. CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol 2008, 28:615-621.
36. Brown E.J., Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001, 11:130-135.
37. Kaczorowski D.J., Billiar T.R. Targeting CD47: NO limit on therapeutic potential. Circ Res 2007, 100:602-603.
38. Chung J., Gao A.G., Frazier W.A. Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3. J Biol Chem 1997, 272:14740-14746.
39. Isenberg J.S., Romeo M.J., Yu C., Yu C.K., Nghiem K., Monsale J., et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 2008, 111:613-623.
40. Isenberg J.S., Shiva S., Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009, 21:52-62.
41. Maxhimer J.B., Shih H.B., Isenberg J.S., Miller T.W., Roberts D.D. Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg 2009, 124:1880-1889.